Vivek Subbiah: First-in human phase 1 dose-escalation study of BT5528 in Patients With Advanced Solid Tumors

Vivek Subbiah shared a post on X:

“Hot of the press – Pleased to share our paper just before ESMO24. Huge congratulations to our early phase 1 clinical trials team Sarah Cannon Docs for the publication Journal of Clinical Oncology, American Society of Clinical Oncology.

 First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors- Journal of Clinical Oncology- spearhead by Meredith McKean, Babar Bashir, Elisa, Tobias Arkenau & many of our drug development leaders across all our phase 1.

Exhilarating discussions today with Meredith McKean drug development & melanoma leader SCRI Oncology Partners before she heads out for the ESMO meeting.”

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

Authors:  Babar Bashir, Judy S. Wang, Gerald Falchook, Elisa Fontana, Hendrik-Tobias Arkenau, Louise Carter, Rachel Galot, Bristi Basu, Alastair Greystoke, Vivek Subbiah, Debra L. Richardson, Hanna Orr, Gavin Bennett, Rajiv Sharma, Hongmei Xu, Paola Paganoni, Carly Campbell, and Meredith McKean

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.